Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers

Huntington Disease Clinical Trial

— TPMH  

Official title:

Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04630574
• Other study ID #: CHUBX 2018/67
• Status: Completed
• Start date: February 23, 2021
• Est. completion date: February 5, 2024

Study information

• Verified date: February 2024
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.

Description:

Huntington's disease (HD) is a neurodegenerative disorder of the central nervous system, of genetic etiology. It manifests itself in motor, cognitive and psychiatric disorders, which progressively worsen until the patient is grabbed. Motor speech performance disorders are present from the early stage of the disease. These difficulties, which progressively worsen until the end of the patient's life, lead to a communication disorder and constitute a major handicap with social withdrawal, loss of self-esteem and isolation, which are always very painfully experienced by patients and their entourage. Dysarthria in the HD has been very little studied, which makes its speech therapy uncodified. According to the most widely used classification by speech therapists and neurologists, the Darley classification (1975), the speech disorders observed in the HD are included in the heterogeneous group of hyperkinetic dysarthria, whose contours and properties are ill-defined. In this context, a more precise knowledge of speech disorders in the HD appears necessary to identify and characterize the different types of dysarthria and the dysfunctions associated with each level of production (respiration, phonation, resonance, articulation, prosody) and thus improve speech language therapy. The investigators propose to use an acoustic evaluation to support the perceptual evaluation, available in the MonPaGe protocol, to describe the fine characteristics of the speech disorders in the HD and to define objective markers of dysarthria in this disease for francophone patients. Each patient is seen in the framework of his annual follow-up consultation in the Competence Center mdH of Bordeaux University Hospital or in the Reference Center mdH of the hospital Henri Mondor of Créteil, for an evaluation of his speech with the computerized tool MonPaGe. A first speech evaluation with the BECD (Auzou, 2006) during 30 minutes is proposed to exclude very severe dysarthria. At the end of this rapid test subtest, the subjects who obtain a perceptive score <16 are offered the complete assesment of the MonPaGe computerized protocol (30 minutes).The application records directly and anonymously stores speech productions made by the patient.The productions are transmitted to the Phonetics and Phonology Laboratory of Paris (UMR 7018 CNRS / Sorbonne Nouvelle), via a secure large data exchange server and are subject to a perceptual and acoustic evaluation a posteriori.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: February 5, 2024
• Est. primary completion date: February 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• major patients
• francophone patients
• Huntington's disease carriers confirmed by molecular biological analysis
• carriers of pre-symptomatic Huntington's disease: Total Motor Score of the Unified Huntington's Disease Rating Scale <5
• carriers of Huntington's disease at a declared stage: Total Motor Score of the Unified Huntington's Disease Rating Scale = 5
• followed in the Competence Center Huntington's disease Bordeaux Hospital or in the Reference Center Huntington's disease Henri Mondor Hospital of Créteil
• affiliates or beneficiaries of a social security scheme
• Finally, a free, informed and express consent of the patient must be collected.

Exclusion Criteria:

• Huntington's disease patients with severe dysarthria (BECD score> 16), acoustic analysis not being possible on unintelligible speech
• patients placed under the protection of justice

Related Conditions & MeSH terms

• Huntington Disease
• Speech Disorders

Intervention

Other:
• Speech evaluation with the clinical evaluation of dysarthria
A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
• complete assessment of the MonPaGe computerized protocol
The application records directly and anonymously stores speech productions made by the patient.

Locations

Country	Name	City	State
France	Hôpital Henri-Mondor	Créteil
France	Centre Hospitalier Universitaire de Bordeaux	Talence

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Bordeaux	Centre National de la Recherche Scientifique, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of the intelligibility score.	Defined as the number of words correctly recognized by the evaluator (score out of 15).	Day 1
Primary	Determination of the maximum phonation time.	Expressed in milliseconds.	Day 1
Primary	Determination of the phonation characteristics.	Described as the mean and standard deviation of fundamental frequency (in Hz),	Day 1
Primary	Determination of the intensity modulation capacities.	Based on a scale of 0 to 4.	Day 1
Primary	Determination of the Coarticulation.	Expressed in Hz. Extracted from the spectral properties of the acoustic signal of certain words.	Day 1
Primary	Determination of the prosody.	assessed on a scale 0 to 4 on particular sentences.	Day 1
Primary	Determination of the diadocokinesies,	assessed on two scales: precision (0 to 4) and control (0 to 4).	Day 1
Primary	Determination of the articulation rate.	expressed in syllabs per second.	Day 1
Secondary	Determination of the Huntington's disease stage.	The Huntington's disease stage will be determined based on the Total Functional Capacity (TFC) and the Total Motor Score (TMS) scales of the Unified Huntington's Disease Rating Scale: pre-symptomatic stage: TFC = 13 / TMS <5; light stage: TFC =11 / TMS 5 to 20; moderate stage: TFC = 7 to 10 / TMS: 20 to 40	Day 1
Secondary	Determination of the clinical motor forms of the Huntington's disease.	The clinical motor forms of Huntington disease will be determined by the motor UHDRS scale (Total Motor Score), which evaluates oculomotricity, skill and manual planning, bradykinesia, dystonia and rigidity, chorea and walking, balance, lingual protrusion and dysarthria.	Day 1
Secondary	Determination of the level of cognitive impairment	The level of cognitive impairment will be assessed by the cognitive score as per the Unified Huntington's Disease Rating Scale.	Day 1